EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Model‐Informed Deep Q‐Networks to Guide Infliximab Dosing in Pediatric Crohn’s Disease

Kei Irie iD, Phillip Minar iD, Jack Reifenberg iD, Brendan M Boyle, Joshua D Noe, Jeffrey S Hyams iD, Tomoyuki Mizuno iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Kei Irie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Infliximab, Crohn Disease, Gastrointestinal Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Cincinnati Children's Research Foundation, Crohn's and Colitis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Model‐informed precision dosing (MIPD) utilizes pharmacokinetic/pharmacodynamic (PK/PD) models to optimize drug therapy. However, conventional MIPD often requires manual simulation and regimen selection, which are time‐consuming and demand specialized expertise. Reinforcement learning (RL), in which an agent learns optimal decisions through iterative interactions with an environment, offers a scalable and automated alternative. In this study, we developed a model‐informed Deep Q‐Network (DQN) to personalize infliximab dosing for patients with Crohn’s disease. The DQN was trained in a simulation environment incorporating a population PK model, inter‐individual variability, and assay error. Virtual patients with randomly and independently sampled covariates from log‐normal distributions were used to explore dosing strategies at Infusions 1, 3, and 4. Doses ranged from 1 to 10 mg/kg at Infusion 1 and from 1 to 20 mg/kg thereafter, with intervals of 4–12 weeks. The reward function prioritized achieving trough concentrations of 18–26 μg/mL before Infusion 3 and 5–10 μg/mL before Infusions 4 and 5, while penalizing overtreatment and additional infusions. The DQN policy converged after 80,000 episodes, yielding target attainment probabilities (PTAs) of 92.9% and 98.4% at Infusions 4 and 5, respectively, in 1000 virtual patients. High doses (11–20 mg/kg) were selected in only 0.2% of cases. At Infusion 4, 66.8% of patients received an 8‐week interval, and 57.3% at Infusion 5. Retrospective real‐world validation showed that patients whose actual doses matched DQN recommendations had trough levels significantly closer to target ranges. These findings support the feasibility of using DQN‐based agents to enhance and automate infliximab individualized dosing in pediatric populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabCrohn DiseaseGastrointestinal AgentsHumansReinforcement Machine LearningChildPrecision MedicineComputer Simulation

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • University of Cincinnati School of Medicine, Cincinnati, Ohio, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.

ORCID-Profile: Kei Irie, Phillip Minar, Jack Reifenberg, Jeffrey S Hyams, Tomoyuki Mizuno

Förderung

  • NIDDK NIH HHS
  • Cincinnati Children's Research Foundation
  • Crohn's and Colitis Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health
  • Cincinnati Children’s Research Foundation

Zitieren

APA

Irie, K., Minar, P., Reifenberg, J., Boyle, B. M., Noe, J. D., Hyams, J. S., & Mizuno, T. (2026). Model‐Informed Deep Q‐Networks to Guide Infliximab Dosing in Pediatric Crohn’s Disease. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70118

Vancouver

Irie K, Minar P, Reifenberg J, Boyle BM, Noe JD, Hyams JS, et al. Model‐Informed Deep Q‐Networks to Guide Infliximab Dosing in Pediatric Crohn’s Disease. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70118

BibTeX
@article{Irie2026,
  author = {Irie, Kei and Minar, Phillip and Reifenberg, Jack and Boyle, Brendan M and Noe, Joshua D and Hyams, Jeffrey S and Mizuno, Tomoyuki},
  title = {Model‐Informed Deep Q‐Networks to Guide Infliximab Dosing in Pediatric Crohn’s Disease},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70118}
}
Kostenlos starten →